Tower Research Capital LLC TRC Purchases 26,565 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Tower Research Capital LLC TRC boosted its position in 10x Genomics, Inc. (NASDAQ:TXG) by 632.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,764 shares of the company’s stock after buying an additional 26,565 shares during the period. Tower Research Capital LLC TRC’s holdings in 10x Genomics were worth $442,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of TXG. Assenagon Asset Management S.A. acquired a new position in shares of 10x Genomics in the 4th quarter valued at about $26,308,000. ARK Investment Management LLC lifted its stake in 10x Genomics by 11.1% in the fourth quarter. ARK Investment Management LLC now owns 11,944,057 shares of the company’s stock valued at $171,517,000 after buying an additional 1,193,712 shares during the period. SVB Wealth LLC bought a new position in shares of 10x Genomics during the 4th quarter worth approximately $7,505,000. Trexquant Investment LP grew its position in shares of 10x Genomics by 196.2% during the 4th quarter. Trexquant Investment LP now owns 594,611 shares of the company’s stock worth $8,539,000 after buying an additional 393,854 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of 10x Genomics in the 4th quarter valued at $5,557,000. Institutional investors own 84.68% of the company’s stock.

Insiders Place Their Bets

In other 10x Genomics news, Director Alan Mateo purchased 40,000 shares of 10x Genomics stock in a transaction that occurred on Friday, February 21st. The shares were bought at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the acquisition, the director now directly owns 61,691 shares in the company, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the transaction, the insider now directly owns 335,324 shares in the company, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 10.03% of the company’s stock.

10x Genomics Price Performance

TXG opened at $8.38 on Wednesday. 10x Genomics, Inc. has a one year low of $6.78 and a one year high of $29.37. The company has a fifty day moving average price of $9.34 and a 200-day moving average price of $12.95. The firm has a market capitalization of $1.02 billion, a P/E ratio of -5.51 and a beta of 2.01.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, analysts expect that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on TXG shares. Barclays reduced their price target on shares of 10x Genomics from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. UBS Group decreased their price objective on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Stifel Nicolaus lowered their target price on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Leerink Partnrs lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 13th. Finally, Citigroup lowered their price objective on shares of 10x Genomics from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, 10x Genomics presently has a consensus rating of “Hold” and a consensus price target of $19.79.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.